What is HC Wainwright’s Estimate for CASI Q1 Earnings?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for CASI Pharmaceuticals in a report issued on Wednesday, April 9th. HC Wainwright analyst S. Lee expects that the biotechnology company will post earnings of ($0.61) per share for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q2 2025 earnings at ($0.60) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.08) EPS, FY2028 earnings at ($1.15) EPS and FY2029 earnings at ($1.03) EPS.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its earnings results on Monday, March 31st. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.19). The business had revenue of $13.36 million during the quarter, compared to analyst estimates of $7.39 million. CASI Pharmaceuticals had a negative net margin of 143.18% and a negative return on equity of 181.52%.

Separately, StockNews.com started coverage on shares of CASI Pharmaceuticals in a report on Saturday. They set a “hold” rating on the stock.

CASI Pharmaceuticals Stock Up 4.7 %

CASI Pharmaceuticals stock opened at $2.00 on Friday. CASI Pharmaceuticals has a twelve month low of $1.88 and a twelve month high of $7.67. The company has a debt-to-equity ratio of 1.38, a quick ratio of 2.32 and a current ratio of 3.20. The firm has a market cap of $24.60 million, a PE ratio of -0.90 and a beta of 0.66. The firm’s 50 day moving average price is $2.27 and its two-hundred day moving average price is $3.52.

Institutional Investors Weigh In On CASI Pharmaceuticals

A hedge fund recently raised its stake in CASI Pharmaceuticals stock. Woodline Partners LP increased its position in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 226.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 99,690 shares of the biotechnology company’s stock after buying an additional 69,158 shares during the period. Woodline Partners LP owned 0.64% of CASI Pharmaceuticals worth $282,000 at the end of the most recent reporting period. 22.23% of the stock is currently owned by institutional investors.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.